MiNK Therapeutics has made a significant advancement in cancer treatment, as highlighted by the recent publication of a case study in Nature’s Oncogene. The study details a remarkable instance of complete remission in a patient with metastatic testicular cancer after undergoing treatment with agenT-797, an innovative allogeneic invariant natural killer T (iNKT) cell therapy.
In this particular case, the patient had exhausted multiple treatment options, including platinum-based chemotherapy, autologous stem cell transplant, and several immune checkpoint inhibitors (ICIs), yet continued to experience disease progression. Following a single infusion of agenT-797 in combination with nivolumab, the patient achieved a complete clinical, radiologic, and biochemical remission, maintaining this state with no evidence of disease more than two years later. Notably, donor iNKT cells were detectable for up to six months post-infusion, and the treatment was reported to have been well-tolerated, without serious adverse effects such as cytokine release syndrome or graft-versus-host disease.
Dr. Benjamin Garmezy from the Sarah Cannon Research Institute emphasized the significance of this case, stating it showcases the potent potential of iNKT cell therapy in tackling even the most challenging forms of cancer. This promising data contributes to a growing body of evidence supporting the efficacy of agenT-797 in treating solid tumors, including insights presented at the 2025 AACR Immuno-Oncology meeting. The data showed early positive indicators of immune activation and tumor control in gastric cancer patients who had previously been resistant to other forms of immunotherapy. In particular, some patients exhibited extended survival rates exceeding 12 months—an exceptional outcome in this treatment context.
MiNK Therapeutics continues to focus on its development of allogeneic iNKT cell therapies, which represent a new frontier in cancer treatment. With ongoing clinical trials, including a Phase 2 trial in gastric cancer actively enrolling participants, the company aims to further validate its innovative approach in the fight against various cancers.
MiNK Therapeutics is dedicated to redefining cancer treatment through scalable, accessible, and effective immunotherapies that harness the body’s own immune system. This new report not only reinforces the promise of iNKT cell therapies but also instills hope for patients battling cancer, indicating that there are new avenues of treatment that may lead to long-lasting remission.